CLAIMS

1. Use of tasimelteon in the manufacture of a medicament for the treatment of delayed sleep phase disorder (DSPD) in a patient having a genotype associated with DSPD,

wherein the genotype associated with DSPD is one or more genotype selected from a group consisting of: GG at the rs12188518 single nucleotide polymorphism (SNP) locus and CC at the rs11248864 SNP locus,

wherein a dose of tasimelteon effective to advance the sleep time of the patient is to be administered to the patient once daily before a target bedtime.

2. The use of claim 1, wherein the medicament is formulated for oral administration.

3. The use of claim 2, wherein the medicament is formulated for once daily oral administration.

4. The use of claim 3, wherein the medicament is formulated for delivery of an oral daily dose of tasimelteon of 10 mg to 100 mg.

5. The use of claim 4, wherein the medicament is formulated for delivery of an oral daily dose of tasimelteon of 20 mg to 50 mg.

6. The use of claim 5, wherein the medicament is formulated for delivery of an oral daily dose of tasimelteon of 20 mg.

7. The use of claim 1, wherein the medicament is formulated for delivery of a single daily dose of tasimelteon effective to advance a sleep time of the patient.

8. The use of claim 1, wherein the genotype associated with DSPD is GG at the rs12188518 SNP locus.

9. The use of claim 1, wherein the genotype associated with DSPD is CC at the rs11248864 SNP locus.